{"podcast":{"title":"Nucleate Podcast","slug":"nucleate-podcast-6322042","podcast_index_feed_id":6322042,"rss_url":"https://feeds.simplecast.com/OdcQl6Pu","website_url":"https://nucleate-signal.simplecast.com","image_url":"https://image.simplecastcdn.com/images/ed52f7f3-cb55-48af-ae20-82bc5484ef83/a79cf5fe-a623-40da-8d8f-966d626b56de/3000x3000/youtube-20logo.jpg?aid=rss_feed","author":"Nucleate","episode_count":45,"summary":"Nucleate is the new voice for next generation biotech leaders.","last_synced_at":"2026-06-04T14:21:51.754137+00:00","page_url":"https://stenobird.com/podcast/nucleate-podcast-6322042"},"episode":{"title":"Turning Genomic Insights into Breakthrough Therapies | Peter Campbell, CSO of Quotient Therapeutics","slug":"turning-genomic-insights-into-breakthrough-therapies-peter-campbell-cso-of-quotient-therapeutics","published_at":"2025-05-28T10:00:00+00:00","page_url":"https://stenobird.com/podcast/nucleate-podcast-6322042/turning-genomic-insights-into-breakthrough-therapies-peter-campbell-cso-of-quotient-therapeutics","show_page_url":"https://stenobird.com/podcast/nucleate-podcast-6322042","url":"https://nucleate-signal.simplecast.com/episodes/turning-genomic-insights-into-breakthrough-therapies-peter-campbell-cso-of-quotient-therapeutics-FVozM2mz","audio_url":"https://cdn.simplecast.com/audio/6a0defb6-ad56-4c08-b015-fea36f1c159f/episodes/7b922ce3-8ba5-4508-8802-faef9d73fa3d/audio/e94a85ff-d2a5-49d4-9c4c-8f1468528bf9/default_tc.mp3?aid=rss_feed&feed=OdcQl6Pu","summary":"In this episode of the Nucleate Podcast, Dr Peter Campbell traces his scientific journey from a medical student in New Zealand to a pioneering genomics researcher and startup founder. Initially struggling with traditional medical training, Campbell discovered his passion for computational biology while working at the Sanger Institute, where he was instrumental in early cancer genome sequencing efforts. His research evolved from exploring cancer mutations to investigating genetic changes in normal tissues, revealing an unexpected and complex landscape of cellular evolution. This work caught the attention of Flagship Pioneering, leading to the creation of Quotient Therapeutics, a company focused on understanding how somatic mutations drive disease processes and potentially enable personalized medical treatments. Campbell discusses the platform's approach to identifying meaningful mutations, their potential therapeutic applications, and the partnership with Pfizer in cardiovascular and renal disease research. Throughout the conversation, he candidly compares the differences between academic and startup environments, emphasizing the importance of collaboration, efficiency, and storytelling. The episode provides a compelling narrative of scientific discovery, entrepreneurship, and the potential of genomics to transform our understanding of human health and disease.","meta_description":"In this episode of the Nucleate Podcast, Dr Peter Campbell traces his scientific journey from a medical student in New Zealand to a pioneering genomics re…","key_points":[],"chapters":[],"topics":[],"duration_seconds":4764,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/nucleate-podcast-6322042/episodes/turning-genomic-insights-into-breakthrough-therapies-peter-campbell-cso-of-quotient-therapeutics/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/nucleate-podcast-6322042/turning-genomic-insights-into-breakthrough-therapies-peter-campbell-cso-of-quotient-therapeutics.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]}}